CCHW:CNSX-Columbia Care Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 2.62

Change

+0.10 (+3.97)%

Market Cap

CAD 0.98B

Volume

0.08M

Avg Analyst Target

CAD 5.00 (+90.84%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Columbia Care Inc (CCHW) Stock Analysis:
Based on the Columbia Care Inc stock forecasts from 1 analysts, the average analyst target price for Columbia Care Inc is CAD 5.00 over the next 12 months. Columbia Care Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Columbia Care Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Columbia Care Inc’s stock price was CAD 2.62. Columbia Care Inc’s stock price has changed by +5.22% over the past week, -14.94% over the past month and -62.84% over the last year.

About

Columbia Care Inc. cultivates, manufactures, and provides cannabis-based health and wellness solutions, and derivative products. It offers flowers, edibles, oils, and tablets under the Cannabist, Seed & Strain, Triple Seven, gLeaf, Classix, Press, Amber, and Platinum Label CBD br ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

+0.01 (+0.13%)

CAD5.71B N/A 21.30
GTII:CA Green Thumb Industries Inc

-0.30 (-1.94%)

CAD3.93B 32.47 10.75
TRUL:CA Trulieve Cannabis Corp

-0.28 (-1.52%)

CAD3.39B 121.35 16.72
VRNO:CA Verano Holdings Corp

+0.14 (+1.52%)

CAD2.85B 13.46 14.61
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
CL:CA Cresco Labs Inc

-0.13 (-2.58%)

CAD1.55B N/A 20.98
TER:CA TerrAscend Corp

+0.10 (+2.04%)

CAD1.54B 360.77 21.11
FFNT:CA 4Front Ventures Corp

-0.03 (-3.19%)

CAD0.60B N/A N/A
JUSH:CA Jushi Holdings Inc

-0.06 (-2.47%)

CAD0.51B N/A 7.59
LHS:CA Liberty Health Sciences Inc

N/A

CAD0.51B 147.00 13.82

ETFs Containing CCHW:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.62% 75% C 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.62% 75% C 66% D
Trailing 12 Months  
Capital Gain -64.01% 57% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.01% 57% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.51% 54% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.51% 54% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 22.42% 85% B 81% B-
Risk Adjusted Return -46.87% 42% F 30% F
Market Capitalization 0.98B 94% A 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.32 56% F 65% D
Price / Cash Flow Ratio -1,868.01 100% A+ 100% A+
EV/EBITDA 127.53 10% F 7% F
Management Effectiveness  
Return on Equity -29.63% 70% C- 74% C
Return on Invested Capital -6.59% 77% C+ 77% C+
Return on Assets -1.48% 84% B 92% A-
Debt to Equity Ratio 27.83% 28% F 21% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.58 24% F 19% F
Short Percent 0.15% 24% F 22% F
Beta 1.47 40% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.